Brokerage Firm Target Review on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

During the most recent trading session, shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) ┬áchanged +5.05%. Street analysts that track the company are anticipating the stock to go to $436.73 within the next year. Target price projections may vary greatly depending on the specific analyst providing data. This consensus target is compiled using analysts polled by Thomson Reuters. 

Sell-side analysts are able to use multiple metrics in order to help calculate target price estimates. A widely used metric is a company’s preice to earnings ratio. This calculation is derived from dividing the current share price by the projected earnings per share. Regeneron Pharmaceuticals, Inc. currently has a P/E Ratio of 54.39. Investors might also evaluate a company’s PEG or price to earnings growth ratio. The PEG ratio represents the ratio of the price to earnings to the anticipated future growth rate of the company. If a company has a PEG Ratio under one, it may be seen as undervalued. If a company has a PEG Ratio over one, it may represent that the company is overvalued. A PEG Ratio near one may be viewed as fair value. Currently, the company has a PEG Ratio of 1.58.

Looking at stock performance, company shares have recently traded $-6.63 away from the 50-day moving average of $379.63 and $-14.73 away from the 200-day moving average of $387.73. The stock has been recently noted -27.05% off of the 52-week high of 511.31 and +14.65% off of the 52-week low of 325.35. Monitoring the stock price relative to moving averages and highs and lows for the year may help evaluate the value of the stock in the future. 

Leave a Comment